제놀루션
Financials
Valuation Metrics
제놀루션's Market Cap is ₩249B. At end of 2025 it was ₩364B. Ranked #2166 of 2,436 in KR market (top 89%), #1398 of 1,649 on KOSDAQ (top 85%), #220 of 234 in Pharmaceuticals, Biotechnology & Life Sciences (top 94%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 24.95B KRW | KR#2,166/2,436 Sec#220/234 |
| Revenue | 9.82B KRW | KR#2,292/2,436 Sec#178/234 |
| Net Income | -9.90B KRW | KR—/2,436 Sec—/234 |
| Total Assets | 94.35B KRW | KR#1,787/2,436 Sec#145/234 |
| Net Assets | 68.32B KRW | KR#1,661/2,436 Sec#144/234 |
| Employees | 86 | KR#1,741/2,436 Sec#137/234 |
| Value | ||
| P/B | 0.37x | KR#507/2,436 Sec#18/234 |
| P/S | 2.54x | KR#1,961/2,436 Sec#115/234 |
| FCF Yield | -29.28% | KR—/2,436 Sec—/234 |
| Profitability | ||
| ROE | -14.48% | KR#1,982/2,436 Sec#156/234 |
| ROA | -10.49% | KR#2,091/2,436 Sec#163/234 |
| Op. Margin | -76.76% | KR#2,288/2,436 Sec#169/234 |
| Revenue Growth | 20.16% | KR#637/2,436 Sec#61/234 |
| Financial Health | ||
| Debt Ratio | 138.09% | KR#1,001/2,436 Sec#116/234 |
| Total Debt | 9.00B KRW | KR#1,652/2,436 Sec#151/234 |
| FCF | -7.31B KRW | KR#1,612/2,436 Sec#134/234 |
| Cash | 18.22B KRW | KR#1,294/2,436 Sec#98/234 |
| Current Ratio | 1.30x | KR#1,464/2,436 Sec#156/234 |
| Dividend | ||
| Div. Growth | 0.00% | KR—/2,436 Sec—/234 |
| Performance | ||
| 1Y Return | -38.53% | KR#1,751/2,436 Sec#155/234 |
| 1M Return | -3.35% | KR#1,005/2,436 Sec#88/234 |
| From 52W High | -54.06% | KR#1,316/2,436 Sec#112/234 |
| 1Y MDD | -60.23% | KR#1,425/2,436 Sec#114/234 |
| Trading | ||
| Volume | 34,458 shares | KR#1,770/2,436 Sec#169/234 |
| Foreign Own. | 1.61% | KR—/2,436 Sec—/234 |
| Per Share | ||
| EPS | -467 KRW | KR—/2,436 Sec—/234 |
| BPS | 3,817 KRW | KR#1,644/2,436 Sec#127/234 |
Company Info
The company, established in 2006, commenced manufacturing biological products and was listed on KOSDAQ in 2020. It operates in two main sectors: precision medicine, selling nucleic acid extraction reagents and automated equipment, and green bio, developing animal pharmaceuticals and crop protection agents using RNA interference technology. In 2024, it received approval for Honeyguard-R Solution, the world's first gene therapy for honeybee Sacbrood disease. The company is further expanding its business through R&D for Nosema disease treatments and eco-friendly RNA pesticides. Genolution is headquartered in Gangseo-gu, Seoul Metropolitan City.